---
title: "BAIYA CORPORATION released its first-quarter performance, with a net profit attributable to shareholders of 131 million yuan, a year-on-year increase of 27.27%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236540380.md"
description: "According to the Zhitong Finance APP, BAIYA CORPORATION released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 999.5 million yuan, a year-on-year increase of 30.10%. The net profit attributable to shareholders of the listed company was 131 million yuan, a year-on-year increase of 27.27%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 129 million yuan, a year-on-year increase of 32.40%"
datetime: "2025-04-18T08:21:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236540380.md)
  - [en](https://longbridge.com/en/news/236540380.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236540380.md)
generator: "portal-rs"
---

# BAIYA CORPORATION released its first-quarter performance, with a net profit attributable to shareholders of 131 million yuan, a year-on-year increase of 27.27%

According to the Zhitong Finance APP, BAIYA CORPORATION (003006.SZ) released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 995 million yuan, a year-on-year increase of 30.10%. The net profit attributable to shareholders of the listed company was 131 million yuan, a year-on-year increase of 27.27%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 129 million yuan, a year-on-year increase of 32.40%

### Related Stocks

- [003006.CN](https://longbridge.com/en/quote/003006.CN.md)

## Related News & Research

- [Xinhua Pharma unit Xincat’s azithromycin tablets pass China generic consistency evaluation](https://longbridge.com/en/news/297485179.md)
- [Klaria Pharma plans listing of new warrants linked to rights issue at SEK 0.6 strike](https://longbridge.com/en/news/297582995.md)
- [Tornator: Revenue and profit dipped, but investments and financial strength support a positive outlook](https://longbridge.com/en/news/297314989.md)
- [Nedbank wins Kenya central bank approval for bid to buy 66% of NCBA Group](https://longbridge.com/en/news/297512562.md)
- [PharmaEssentia’s Besremi receives FDA approval for ET](https://longbridge.com/en/news/297630746.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**